News from adamas pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 04, 2012, 07:00 ET

Adamas Pharmaceuticals Presents Update On Nurelin™ Program At Cambridge Healthtech Institute's Parkinson's Conference

 Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin™ (amantadine HCl...

May 15, 2012, 07:00 ET

Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™

 Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the...

Sep 28, 2011, 07:00 ET

Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary...

Apr 28, 2010, 07:00 ET

Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy is Well Tolerated in a Pilot Study of Immunocompromised Patients With Influenza A

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination...

Mar 15, 2010, 06:30 ET

Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that...

Feb 22, 2010, 09:30 ET

Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains

Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the...

Nov 19, 2009, 08:30 ET

Adamas Pharmaceuticals Expands Clinical Study for Triple-Combination Antiviral Drug Therapy in Immune-Compromised Patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary...

Sep 13, 2009, 13:45 ET

In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple...

Sep 03, 2009, 13:00 ET

Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting

Adamas Pharmaceuticals, Inc., a privately held company, announced today that new research data will be delivered as an oral presentation during...

Aug 25, 2009, 10:30 ET

Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its management team, naming Michael D. Coffee,...

Aug 18, 2009, 10:30 ET

Adamas Pharmaceuticals Raises $40 Million in Series D Financing

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by...

Aug 18, 2009, 10:30 ET

Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement...